What pulmonary function test thresholds (e.g., forced expiratory volume in one second, diffusing capacity for carbon monoxide, maximal oxygen consumption, 6‑minute walk distance) define eligibility for thoracic radiotherapy?

Ideal Lung Function Test Criteria for Radiotherapy

For thoracic radiotherapy eligibility, FEV₁ and DLCO should both be at least 50% of age-adjusted predicted values, though no absolute DLCO threshold contraindication exists and DLCO measurement is essential for risk stratification despite insufficient data to define a strict cutoff. 1, 2

Primary Pulmonary Function Parameters

FEV₁ (Forced Expiratory Volume in 1 Second)

• Minimum threshold: ≥50% of age-adjusted predicted value for patients enrolled in major thoracic radiotherapy trials 1
• This threshold represents the standard used in clinical trials demonstrating safe concurrent chemoradiotherapy delivery 1
• Most patients successfully treated with definitive radiotherapy (≥60 Gy) had FEV₁ ≥50% predicted 1

DLCO (Diffusing Capacity for Carbon Monoxide)

• Minimum threshold: ≥50% of age-adjusted predicted value based on clinical trial populations 1
• DLCO measurement is strongly recommended as essential for pre-radiotherapy risk stratification, though insufficient data exist to define an absolute contraindication threshold 2
• The 2025 European Respiratory Society/European Society of Thoracic Surgeons guidelines emphasize DLCO as essential despite acknowledging very low certainty of evidence for specific thresholds in radiotherapy 2

Risk Stratification Framework

DLCO-Based Risk Categories

While no absolute contraindication exists, consider these risk strata for counseling and monitoring:

• DLCO ≥80%: Lower risk baseline 2
• DLCO 60-79%: Moderate risk 2
• DLCO 40-59%: Higher risk 2
• DLCO <40%: Highest risk, though not an absolute contraindication 2

Clinical Context Considerations

• Performance status matters: Most safely treated patients had WHO performance score ≤1 (only 3% had score ≥2) 1
• Age alone should not exclude: Elderly patients (≥70 years) with reasonable lung function can be safely treated, though toxicities may be more pronounced 1
• Post-induction therapy: If using induction therapy before radiotherapy, re-evaluate with DLCO <80% as a threshold for increased concern 2

Important Caveats and Pitfalls

The Evidence Gap

• Critical limitation: There is acknowledged lack of data on how pulmonary function tests influence radiation-induced lung toxicity 1
• The 50% thresholds derive from clinical trial inclusion criteria rather than outcomes-based evidence demonstrating harm below these values 1
• No prospective data exist defining optimal thresholds for patients with poor lung function or major comorbidities 1

DLCO Changes During Treatment

• DLCO declines correlate with radiation pneumonitis severity: median reductions of 10.7% (Grade 0), 13% (Grade 1), 22.1% (Grade 2), and 35.2% (Grade 3) 3
• After stereotactic body radiotherapy, DLCO typically declines by approximately 5.2% at 12 months, though this represents grade 1 toxicity and does not predict worse overall survival 4
• Lower baseline or post-treatment DLCO values do not predict worse overall survival in SBRT patients 4

Parameters NOT Routinely Required

• Peak oxygen consumption (VO₂max): Failed to predict post-operative pulmonary complications even in surgical candidates and is not established for radiotherapy eligibility 5
• 6-minute walk distance: Not validated as a radiotherapy eligibility criterion 2
• Lung volumes (FVC, TLC): Show minimal change after radiotherapy and are not primary eligibility determinants 4

Practical Algorithm

Step 1: Measure baseline FEV₁ and DLCO before radiotherapy 2

Step 2: Apply thresholds:

• If both FEV₁ and DLCO ≥50% predicted → Proceed with standard radiotherapy planning 1
• If either FEV₁ or DLCO <50% predicted → Increased risk but not absolute contraindication; consider dose-volume constraints more carefully 1, 2

Step 3: Optimize dose-volume parameters regardless of baseline function:

• Keep V₂₀ (volume receiving ≥20 Gy) at 35-37% 1
• Keep mean lung dose at 20-23 Gy 1

Step 4: Monitor DLCO during and after treatment as objective measure of radiation pneumonitis 3